Abstract | BACKGROUND: METHODS AND RESULTS: We measured serum arylesterase activity in 760 subjects with impaired left ventricular systolic function (left ventricular ejection fraction <50%), and prospectively followed major adverse cardiac events (including death, nonfatal myocardial infarction, and stroke) for 3 years. In our study cohort (mean age, 64±11 years; 74% men; median left ventricular ejection fraction, 35%; median creatinine clearance, 96 mg/dL), mean serum arylesterase activity (98±25 μmol/L/min/mL) was lower compared with that in healthy control subjects (mean, 115±26 μmol/L/min/mL, P<0.01) but higher compared with advanced decompensated heart failure subjects (mean, 69±22 μmol/L/min/mL, P<0.01). Within our cohort, there was modest correlation between serum arylesterase activity and high-density lipoprotein cholesterol (r=0.33, P<0.01) as well as B-type natriuretic peptide (r=-0.23, P<0.01). Lower serum arylesterase activity was a strong predictor of poorer outcomes (hazard ratio, 2.94; 95% confidence interval, 1.54, 5.62; P<0.001). After adjusting for traditional risk factors, medication use, B-type natriuretic peptide, and creatinine clearance, lower serum arylesterase still conferred an increased risk of major adverse cardiac events at 3 years (hazard ratio, 2.69; 95% confidence interval, 1.37 to 5.28; P=0.004). CONCLUSIONS:
|
Authors | W H Wilson Tang, Yuping Wu, Shirley Mann, Michael Pepoy, Kevin Shrestha, Allen G Borowski, Stanley L Hazen |
Journal | Circulation. Heart failure
(Circ Heart Fail)
Vol. 4
Issue 1
Pg. 59-64
(Jan 2011)
ISSN: 1941-3297 [Electronic] United States |
PMID | 21062973
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antioxidants
- Biomarkers
- Lipoproteins, HDL
- Carboxylic Ester Hydrolases
- arylesterase
- Aryldialkylphosphatase
|
Topics |
- Aged
- Antioxidants
(metabolism)
- Aryldialkylphosphatase
(metabolism)
- Biomarkers
(blood)
- Carboxylic Ester Hydrolases
(blood)
- Case-Control Studies
- Cohort Studies
- Disease Progression
- Female
- Follow-Up Studies
- Heart Failure, Systolic
(complications, metabolism)
- Humans
- Lipoproteins, HDL
(metabolism)
- Longitudinal Studies
- Male
- Middle Aged
- Myocardial Infarction
(epidemiology)
- Predictive Value of Tests
- Prognosis
- Prospective Studies
- Risk Factors
- Stroke
(epidemiology)
- Stroke Volume
(physiology)
- Ventricular Dysfunction, Left
(complications, metabolism)
|